SG11202110504XA - ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF - Google Patents
ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOFInfo
- Publication number
- SG11202110504XA SG11202110504XA SG11202110504XA SG11202110504XA SG11202110504XA SG 11202110504X A SG11202110504X A SG 11202110504XA SG 11202110504X A SG11202110504X A SG 11202110504XA SG 11202110504X A SG11202110504X A SG 11202110504XA SG 11202110504X A SG11202110504X A SG 11202110504XA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- pyroglutamate
- amyloid
- pyroglutamate amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823785P | 2019-03-26 | 2019-03-26 | |
| PCT/EP2020/058395 WO2020193644A1 (en) | 2019-03-26 | 2020-03-25 | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110504XA true SG11202110504XA (en) | 2021-10-28 |
Family
ID=70008544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110504XA SG11202110504XA (en) | 2019-03-26 | 2020-03-25 | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20220177560A1 (en) |
| EP (1) | EP3946603A1 (en) |
| JP (1) | JP2022526528A (en) |
| KR (1) | KR20210143858A (en) |
| CN (1) | CN113891746A (en) |
| AU (1) | AU2020245031A1 (en) |
| BR (1) | BR112021019107A2 (en) |
| CA (1) | CA3134785A1 (en) |
| CL (2) | CL2021002473A1 (en) |
| CO (1) | CO2021014028A2 (en) |
| CR (1) | CR20210492A (en) |
| DO (1) | DOP2021000199A (en) |
| EA (1) | EA202192606A1 (en) |
| EC (1) | ECSP21079184A (en) |
| IL (1) | IL286634A (en) |
| JO (1) | JOP20210265A1 (en) |
| MA (1) | MA55491A (en) |
| MX (1) | MX2021011715A (en) |
| PE (1) | PE20212266A1 (en) |
| SG (1) | SG11202110504XA (en) |
| WO (1) | WO2020193644A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202216760A (en) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | Anti-abeta antibodies |
| US11802149B2 (en) * | 2021-10-28 | 2023-10-31 | Abbvie Inc. | Anti-amyloid beta antibodies and methods of using the same |
| TW202346355A (en) | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
| TW202400636A (en) | 2022-03-11 | 2024-01-01 | 比利時商健生藥品公司 | Multispecific antibodies and uses thereof |
| WO2023170295A1 (en) | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
| WO2024133925A1 (en) | 2022-12-22 | 2024-06-27 | Bioarctic Ab | Antibody which binds to abetape3 |
| CN118459582A (en) * | 2024-07-11 | 2024-08-09 | 苏州近岸蛋白质科技股份有限公司 | Anti-pyroglutamic acid modified beta amyloid antibody and application thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| US5642870A (en) | 1992-08-05 | 1997-07-01 | Sargis; Ike | Switch stand |
| US5761894A (en) | 1996-09-25 | 1998-06-09 | Magic Circle Corporation | Grass striping attachment for lawn mowers |
| US9907485B2 (en) | 2004-10-15 | 2018-03-06 | Brainlab Ag | Targeted immunization and plaque destruction against Alzheimer's disease |
| ES2396555T3 (en) * | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Antibodies that recognize beta amyloid peptide |
| PL1954718T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US20110182809A1 (en) | 2008-07-09 | 2011-07-28 | University Of Zurich | Method of Promoting Neurogenesis |
| CN102131519B (en) | 2008-07-21 | 2016-01-13 | 前体生物药物股份公司 | diagnostic antibody assay |
| WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| AR080243A1 (en) * | 2010-02-23 | 2012-03-21 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| BR112013004056B8 (en) * | 2010-08-12 | 2022-10-18 | Lilly Co Eli | HUMAN-PROJECTED AB ANTI-N3PGLU MONOCLONAL ANTIBODIES, THEIR USE AND PHARMACEUTICAL COMPOSITION INCLUDING THEM |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| ITRM20120383A1 (en) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | METHOD AND KIT FOR DETECTING ANTIBODIES. |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2015191825A1 (en) | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
| PT3177642T (en) * | 2014-08-07 | 2022-02-14 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| BR112018000097A2 (en) * | 2015-07-16 | 2018-09-04 | Probiodrug Ag | humanized antibodies |
| JOP20170004B1 (en) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | ANTl-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| AR107774A1 (en) | 2016-03-16 | 2018-05-30 | Lilly Co Eli | COMBINATION THERAPY, METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE |
| EP3249388A1 (en) | 2016-05-23 | 2017-11-29 | Raman Health Technologies, S.L | Method for diagnosing alzheimer´s disease |
| BR112018075300A2 (en) | 2016-06-07 | 2019-04-30 | Biogen International Neuroscience Gmbh | Methods For Treating Alzheimer's Disease |
| EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
| TWI669119B (en) | 2016-10-21 | 2019-08-21 | 美國禮來大藥廠 | Combination therapy |
| TW201827467A (en) * | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | Antibodies to pyroglutamate amyloid-[beta] and uses thereof |
| JOP20190247A1 (en) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| PE20200695A1 (en) * | 2017-05-02 | 2020-06-16 | Prothena Biosciences Ltd | ANTIBODIES THAT RECOGNIZE TAU |
| JOP20200041A1 (en) | 2017-08-22 | 2020-02-20 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| CN113164777A (en) * | 2018-09-27 | 2021-07-23 | 马伦戈治疗公司 | CSF1R/CCR2 multispecific antibodies |
-
2020
- 2020-03-25 US US17/598,280 patent/US20220177560A1/en active Pending
- 2020-03-25 JO JOP/2021/0265A patent/JOP20210265A1/en unknown
- 2020-03-25 KR KR1020217034312A patent/KR20210143858A/en active Search and Examination
- 2020-03-25 JP JP2021557190A patent/JP2022526528A/en active Pending
- 2020-03-25 EP EP20714579.8A patent/EP3946603A1/en active Pending
- 2020-03-25 CN CN202080039618.2A patent/CN113891746A/en active Pending
- 2020-03-25 BR BR112021019107A patent/BR112021019107A2/en unknown
- 2020-03-25 US US16/829,029 patent/US11236155B2/en active Active
- 2020-03-25 PE PE2021001598A patent/PE20212266A1/en unknown
- 2020-03-25 AU AU2020245031A patent/AU2020245031A1/en active Pending
- 2020-03-25 EA EA202192606A patent/EA202192606A1/en unknown
- 2020-03-25 MX MX2021011715A patent/MX2021011715A/en unknown
- 2020-03-25 WO PCT/EP2020/058395 patent/WO2020193644A1/en active Application Filing
- 2020-03-25 SG SG11202110504XA patent/SG11202110504XA/en unknown
- 2020-03-25 CR CR20210492A patent/CR20210492A/en unknown
- 2020-03-25 CA CA3134785A patent/CA3134785A1/en active Pending
- 2020-03-25 MA MA055491A patent/MA55491A/en unknown
-
2021
- 2021-09-23 IL IL286634A patent/IL286634A/en unknown
- 2021-09-23 DO DO2021000199A patent/DOP2021000199A/en unknown
- 2021-09-23 CL CL2021002473A patent/CL2021002473A1/en unknown
- 2021-10-20 CO CONC2021/0014028A patent/CO2021014028A2/en unknown
- 2021-10-26 EC ECSENADI202179184A patent/ECSP21079184A/en unknown
- 2021-12-17 US US17/554,461 patent/US20220106387A1/en active Pending
-
2022
- 2022-09-29 CL CL2022002670A patent/CL2022002670A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021019107A2 (en) | 2021-11-30 |
| PE20212266A1 (en) | 2021-11-30 |
| KR20210143858A (en) | 2021-11-29 |
| CO2021014028A2 (en) | 2021-10-29 |
| DOP2021000199A (en) | 2022-07-15 |
| ECSP21079184A (en) | 2021-11-30 |
| CL2021002473A1 (en) | 2022-04-22 |
| US20220106387A1 (en) | 2022-04-07 |
| CA3134785A1 (en) | 2020-10-01 |
| AU2020245031A1 (en) | 2021-10-21 |
| JOP20210265A1 (en) | 2023-01-30 |
| JP2022526528A (en) | 2022-05-25 |
| MX2021011715A (en) | 2021-12-10 |
| EP3946603A1 (en) | 2022-02-09 |
| CL2022002670A1 (en) | 2023-03-31 |
| CN113891746A (en) | 2022-01-04 |
| WO2020193644A1 (en) | 2020-10-01 |
| US11236155B2 (en) | 2022-02-01 |
| EA202192606A1 (en) | 2022-01-24 |
| CR20210492A (en) | 2021-11-19 |
| US20200308261A1 (en) | 2020-10-01 |
| IL286634A (en) | 2021-10-31 |
| MA55491A (en) | 2022-02-09 |
| US20220177560A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268527A (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
| IL278846A (en) | Anti-cd3 antibodies and uses thereof | |
| IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
| SG11202110504XA (en) | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF | |
| IL268243A (en) | Antibodies to alpha-synuclein and uses thereof | |
| IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
| ZA201905341B (en) | Antibodies specifically binding to human il-1r7 | |
| EP3534937C0 (en) | Antibodies to pyroglutamate amyloid-beta and uses thereof | |
| EP3725802A4 (en) | Antibodies to alpha-synuclein and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
| IL287816A (en) | Antibody to tigit and use thereof | |
| IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| IL289656A (en) | Anti-tigit antibodies and application thereof | |
| IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
| IL276548A (en) | Bcma-binding antibodies and uses thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| SG11202008579UA (en) | Anti-phf-tau antibodies and uses thereof | |
| IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof |